Dr. Reddy's Laboratories Limited

NYSE:RDY

Drug Manufacturers - Specialty & Generic

Healthcare
$14.98 -1.13%

-$0.15 today

Market cap
$12.48B
Beta
0.26
P/E (TTM)
24.7
EPS (TTM)
$51.40
Dividend yield
0.63%
52W Low $12.19High $15.71

Volume 1.79M

Average 2.39M

RDY Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Dr. Reddy's Laboratories LimitedNYSE: RDY

Weighted Avg Shares (Diluted) · Q2 FY2027 · quarter ended Sep 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q2 FY2027 weighted avg shares (diluted) of 833.33M shares rose 0.0% year over year, in line with the -0.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +0.0% holds above the trailing-twelve-month pace of -0.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
833.33M+0.1% QoQ
Last fiscal yearMar 2026
833.26M-0.1% YoY
LTMSep 2026
833.5M-0.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year-0.1%——
3-year CAGR+0.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2026
833.26M INR
Year-over-year change
-0.1%
4-year CAGR
+0.0%

Weighted Avg Shares (Diluted) vs competitors

How RDY compares with its peers on the latest reported figures

  • RDY's LTM Sep 2026 weighted avg shares (diluted) of 833.5M shares is the 4th highest of the 8 companies compared; the peer median is 374.23M shares.
  • Its year-over-year change of -0.0% is the 5th highest of 7, against a peer median of +1.7%.
  • Over three fiscal years its annual growth of +0.1% compares with a peer median of +1.2%.
RDY Competitors Peer median
Weighted Avg Shares (Diluted) for RDY and competitors
Company Period LTM YoY 3-year CAGR
HLNHaleon plcLTM Jun 20254.56B —-0.8%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 20261.17B +2.4%+1.9%
VTRSViatris Inc.LTM Jun 20261.16B -2.2%-1.3%
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026833.5M -0.0%+0.1%
BHCBausch Health Companies Inc.LTM Jun 2026374.23M +0.9%+1.2%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026326.65M +3.2%+29.1%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202647.36M -8.0%-2.8%
ANIPANI Pharmaceuticals, Inc.LTM Mar 202621.04M +7.6%+9.3%
Peer median (excluding RDY) 374.23M+1.7%+1.2%

Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

INR
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue214.39B245.88B279.16B325.54B353.47B
Cost of Revenue100.55B106.54B115.56B135.11B166.95B
Gross Profit113.84B139.34B163.61B190.43B186.52B
Gross Margin53.1%56.7%58.6%58.5%52.8%
Research & Development17.48B19.38B22.87B27.38B25.31B
Selling, General & Admin62.08B68.03B77.2B93.87B112.34B
Operating Expenses84.36B82.2B95.88B118.59B137.65B
Depreciation & Amortization11.82B12.64B14.84B17.06B21.68B
EBITDA45.08B74.43B88.42B96.67B83.29B
EBITDA Margin21.0%30.3%31.7%29.7%23.6%
Operating Income29.48B57.14B67.73B71.84B48.87B
Operating Margin13.7%23.2%24.3%22.1%13.8%
Interest Income965M1.18B2.28B2.68B8.28B
Interest Expense958M1.43B1.71B2.83B3.93B
Other Income / Expenses2.82B3.22B4.14B4.94B8.81B
Income Before Tax32.3B60.37B71.87B76.78B57.68B
Pre-Tax Margin15.1%24.6%25.7%23.6%16.3%
Income Tax Expense8.73B15.3B16.19B19.54B13B
Net Income23.57B45.07B55.68B56.54B45.09B
Net Margin11.0%18.3%19.9%17.4%12.8%
EPS (Basic)28.4254.2966.8067.8553.92
EPS (Diluted)28.3454.1766.8067.7753.92
Weighted Avg Shares829.41M830.17M833.54M833.31M832.41M
Weighted Avg Shares (Diluted)831.69M831.91M833.54M834.3M833.26M

Dr. Reddy's Laboratories Limited

NYSE:RDY

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.